
Claims

1. A DHODH inhibitor compound for use in a local ocular route administration in a method to treat an ocular disease, wherein the compound is



.

2. The compound for use according to claim 1, wherein the ocular disease is uveitis, dry eye, age-related macular degeneration (AMD), optic neuritis, retrobulbar neuritis, ocular inflammation or discomfort or trauma caused by or associated with the use of contact lenses, ocular inflammation, discomfort or trauma caused by or associated with refractive surgery, blepharitis, an optic nerve disease or disorder, or a conjunctivitis condition.
3. The compound for use according to claim 1 or 2, wherein a subject is suffering from uveitis, dry eye, age-related macular degeneration (AMD), conjunctivitis, keratitis, keratoconjunctivitis, vernal keratoconjunctivitis (VKC), and atopic keratoconjunctivitis (AKC), or the subject is suffering from uveitis, dry eye, age-related macular degeneration (AMD), or conjunctivitis, or the subject is suffering from age-related macular degeneration (AMD).
4. The compound for use according to any one of claims 1 to 3, wherein the ocular disease is caused by an adenovirus.
5. The compound for use according to any one of claims 1 to 4, wherein said compound is administered to the subject in a therapeutically effective amount.
6. The compound for use according to any one of claims 1 to 5, wherein said compound is administered to the subject at least once per day or said compound is administered as a slow release formulation at least once per month, or at least every second month, or at least every third month, preferably at least every sixth month.
7. The compound for use according to any one of claims 1 to 5 in a method for treating an ocular disease through injection of said compound into the vitreous body with a frequency of injections not exceeding one injection per month.
8. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 1 for use in the treatment of an ocular disease.

9. The pharmaceutical composition according to claim 8, comprising the compound according to claim 1, together with a pharmaceutically acceptable excipient therefor.
10. The pharmaceutical composition according to claim 9, wherein the excipient is selected from the group of hydrophilic polymer excipients, tonicity agents, buffers, sugars such as trehalose, mannose, D-galactose, and lactose, preservatives, co-solvents or antioxidants.
11. The pharmaceutical composition according to any one of claims 8 to 10, which is formulated for a local ocular route administration such as intravitreous, topical, periocular injections (subconjunctival, peribulbar, latero-bulbar, retrobulbar, sub-tenon, suprachoroidal), intra- or periocular implants (intrascleral, periscleral, episcleral), intravitreous implants or suprachoroidal implants or particles or polymeric composition, or any releasing systems such as emulsions, solid non-biodegradable or degradable implants or tablets, mini pumps or any topical formulations.
12. The pharmaceutical composition according to any one of claims 8 to 10, which is a sterile eye drop formulation, a suspension, an emulsion, a microsphere formulation or a sterile solution for intravitreal injection.
13. An ophthalmic formulation of a pharmaceutical composition according to any one of claims 8 to 12, optionally in form of a sterile eye drop formulation or as a sterile solution for intravitreal injection.
14. The formulation according to claim 13, wherein the frequency of administration is once daily or in the range from about one to about eight times a day, once per week, once per month, every second month or every third month or every sixth month.
15. The formulation according to claims 13 or 14, wherein a therapeutically effective amount of the compound reaches the posterior segment of the eye.